The U.S. hemodialysis vascular grafts market size is anticipated to reach USD 68.5 million by 2030, growing at a CAGR of 4.5% from 2024 to 2030. One of the primary drivers of the market is the rising prevalence of end-stage renal disease (ESRD). ESRD is a significant public health concern, with a growing number of patients requiring hemodialysis as a life-sustaining treatment. This increasing patient population drives the demand for hemodialysis vascular grafts to create reliable access to dialysis procedures.
There is a noticeable trend towards minimally invasive procedures in the field of vascular access for hemodialysis. Minimally invasive techniques reduce patient discomfort, recovery time, and complications associated with traditional surgical interventions. As a result, healthcare providers are increasingly adopting hemodialysis vascular grafts that support minimally invasive approaches, driving market growth.
In April 2023, the Aspirex mechanical suction thrombectomy system, which employs 6- and 8-F catheters, was approved by the FDA under 510(k) for use by BD (Becton, Dickinson, and Company) to remove acute emboli and clots for hemodialysis access to arteriovenous grafts and native arteriovenous fistulas. This device was introduced in 2022 and operates on a three-pronged mechanism mechanical transportation for effective clot removal through the catheter and out of the channel, continuous clot maceration to prevent clogging, and enhanced clot aspiration.
There is a noticeable trend towards minimally invasive procedures in the field of vascular access for hemodialysis. Minimally invasive techniques reduce patient discomfort, recovery time, and complications associated with traditional surgical interventions. As a result, healthcare providers are increasingly adopting hemodialysis vascular grafts that support minimally invasive approaches, driving market growth.
In April 2023, the Aspirex mechanical suction thrombectomy system, which employs 6- and 8-F catheters, was approved by the FDA under 510(k) for use by BD (Becton, Dickinson, and Company) to remove acute emboli and clots for hemodialysis access to arteriovenous grafts and native arteriovenous fistulas. This device was introduced in 2022 and operates on a three-pronged mechanism mechanical transportation for effective clot removal through the catheter and out of the channel, continuous clot maceration to prevent clogging, and enhanced clot aspiration.
U.S. Hemodialysis Vascular Grafts Market Report Highlights
- As the population ages and the prevalence of conditions such as diabetes and hypertension increases, more individuals require hemodialysis, driving the market for vascular grafts.
- The polytetrafluoroethylene raw material segment dominated the market with a share of around 45.5% in 2023 and is anticipated to witness the fastest CAGR during the forecast period. This is attributed to the benefits associated with the material such as ease of handling, durability, and resistance to infection.
- In June 2023, Merit Medical System Inc. acquired a catheter system from Bluegrass Vascular for USD 32.5 million followed with a larger USD 100 million asset purchase from AngioDynamics.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Hemodialysis Vascular Grafts Market Variables, Trends & Scope
Chapter 4. U.S. Hemodialysis Vascular Grafts Market: Raw Material Estimates & Trend Analysis
Chapter 5. U.S. Hemodialysis Vascular Grafts Market: Regional Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Getinge
- Medtronic
- W. L. Gore & Associates
- LeMaitre
- CryoLife
- Merit Medical Systems
- C.R. Bard, Inc.
- Vascudyne, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 70 |
| Published | May 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 50.2 Million |
| Forecasted Market Value ( USD | $ 68.5 Million |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | United States |
| No. of Companies Mentioned | 8 |
